British AI drug discovery spin-off from DeepMind, backed by Alphabet.
Arm Holdings chief executive Rene Haas says AI could one day help cure cancer, but the path is constrained by chip shortages and a demand surge for AI data centres. Multiple outlets report Haas’s remarks, framing a broaderAI-driven push in healthcare and manufacturing, while flagging supply constraints and broader market excitement.
Anthropic has built a wet lab in the San Francisco Bay Area to accelerate biology work, confirming a shift from in silico research to real-lab experimentation. The move comes amid warnings about AI risks and a looming IPO, with leadership stressing safety while pursuing faster drug development.
Nvidia, AMD, OpenAI, Anthropic and Google have pledged billions to fund the Genesis Mission, an AI initiative across 15 federal agencies to accelerate research. The White House says the program will provide AI tools and compute credits, with Nvidia alone contributing $1 billion. The funding aims to speed breakthroughs in medicine, energy and space.
Anthropic is pitching its Claude models as a catalyst for rapid biological discovery, framing AI as a force to accelerate drug research. Its S-1 highlights life-sciences ambitions and partnerships with pharma giants while Isomorphic Labs is pursuing AI-designed medicines, aiming to design drugs without traditional lab work.